

Publications PhD students

Laboratory of Molecular Neuro-Oncology Prof. Michael Weller

Manuela Silginer

Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor- β pathway in glioblastoma. *Brain*. 2013;136(Pt 2):564-76.

Silginer M, Weller M, Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. *Cell Death Dis*. 2014 23;5:e1012. doi:10.1038/cddis.2013.543

Happold C, Roth P, Silginer M, Florea AM, Lamszus K, Frei K, Deenen R, Reifenberger G, Weller M. Interferon- β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. *Mol Cancer Ther*. 2014;13(4):948-61

Mushfika Ahmad

Ahmad M, Frei K, Willscher E, Stefanski A, Kaulich K, Roth P, Stühler K, Reifenberger G, Binder H, Weller M. How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. *J Neuropathol Exp Neurol*. 2014;73(11):1062-77. doi:10.1097/NEN.0000000000000130

Paula Codó

Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G, Roth P. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. *Oncotarget*. 2014;5(17):7651-62

Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. *Eur J Cancer*. 2015;51(3):382-90

Codó P, Weller M, Kaulich K, Schraivogel D, Silginer M, Reifenberger G, Meister G, Roth P. Control of glioma cell migration and invasiveness by GDF-15. *Oncotarget*. 2016;7(7):7732-46

Nina Stojceva

Stojceva N, Schechtmann G, Sass S, Roth P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis FJ, Weller M, Reifenberger G, Happold C. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. *Oncotarget*. 2016;7(11):12937-50

Happold C, Stojceva N, Silginer M, Weiss T, Roth P, Reifenberger G, Weller M. Transcriptional control of O(6)-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *J Neurochem*. 2018

Shanmugarajan Krishnan

Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G. Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. *Brain*. 2014;137(Pt 2):433-48

Krishnan S, Szabo E, Burghardt I, Frei K, Tabatabai G, Weller M. Modulation of cerebral endothelial cell function by TGF- β in glioblastoma: VEGF-dependent

angiogenesis versus endothelial mesenchymal transition. *Oncotarget*. 2015;6(26):22480-95

Davide Mangani

Mangani D, Weller M, Seyed Sadr E, Willscher E, Seystahl K, Reifenberger G, Tabatabai G, Binder H, Schneider H. Limited role for transforming growth factor- β pathway activation-mediated escape from VEGF inhibition in murine glioma models. *Neuro Oncol*. 2016;18(12):1610-1621

Mangani D, Weller M, Roth P. The network of immunosuppressive pathways in glioblastoma. *Biochem Pharmacol* 2017; 130:1-9

Eleanna Papa

Papa E, Weller M, Weiss T, Ventura E, Burghardt I, Szabó E. Negative control of the HGF/c-MET pathway by TGF- β : a new look at the regulation of stemness in glioblastoma. *Cell Death Dis*. 2017 Dec 13;8(12):3210

Alexandros Papachristodoulou

Papachristodoulou A, Silginer M, Weller M, Schneider H, Hasenbach K, Janicot M, Roth P. Therapeutic targeting of TGF- β ligands in glioblastoma using novel antisense oligonucleotides reduces the growth of experimental gliomas. *Clin Cancer Res*. 2019 Sep 17. pii: clincanres.3024.2017

Çavuşoğlu M, Zhang J, Ielacqua GD, Pellegrini G, Signorell RD, Papachristodoulou A, Brambilla D, Roth P, Weller M, Rudin M, Martin E, Leroux JC, Werner B. Closed-loop cavitation control for focused ultrasound-mediated blood-brain barrier opening by long-circulating microbubbles. *Phys Med Biol*. 2019;64(4):045012

Papachristodoulou A, Signorell RD, Werner B, Brambilla D, Luciani P, Cavusoglu M, Grandjean J, Silginer M, Rudin M, Martin E, Weller M, Roth P, Leroux JC. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. *J Control Release*. 2019 Feb 10;295:130-139

Signorell RD, Papachristodoulou A, Xiao J, Arpagaus B, Casalini T, Grandjean J, Thamm J, Steiniger F, Luciani P, Brambilla D, Werner B, Martin E, Weller M, Roth P, Leroux JC. Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. *Int J Pharm*. 2018;536(1):388-396

Seystahl K, Papachristodoulou A, Burghardt I, Schneider H, Hasenbach K, Janicot M, Roth P, Weller M. Biological Role and Therapeutic Targeting of TGF- β (3) in Glioblastoma. *Mol Cancer Ther*. 2017 Jun;16(6):1177-1186

Elisa Ventura

Papa E, Weller M, Weiss T, Ventura E, Burghardt I, Szabó E. Negative control of the HGF/c-MET pathway by TGF- β : a new look at the regulation of stemness in glioblastoma. *Cell Death Dis*. 2017;8(12):3210

Ventura E, Weller M, Macnair W, Eschbach K, Beisel C, Cordazzo C, Claassen M, Zardi L, Burghardt I. TGF- β induces oncofetal fibronectin that, in turn, modulates TGF- β superfamily signaling in endothelial cells. *J Cell Sci*. 2018;131(1). pii: jcs209619

Ventura E, Weller M, Burghardt I. Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF- β and Furin in Glioma-Initiating Cells. *J Immunol.* 2017 Jun 15;198(12):4569-4574

Caroline von Achenbach

Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, Weller M. Deep, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. *Int J Cancer.* 2019 1;145(1):242-253

von Achenbach C, Weller M, Szabo E. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma. *J Neurochem.* 2018;147(1):99-109

von Achenbach C, Weller M, Kaulich K, Gramatzki D, Zacher A, Fabbro D, Reifenberger G, Szabó E. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. *J Neurochem* in press

Birthe Lohmann

Schneider H, Lohmann B, Wirsching HG, Hasenbach K, Rushing EJ, Frei K, Pruschy M, Tabatabai G, Weller M. Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. *Oncotarget* 2017;8:87124-87135

Le Rhun E, von Achenbach C, Lohmann B, Silginer M, Schneider H, Meetze K, Szabo E, Weller M. Deep, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition. *Int J Cancer* 2019;145:242-253

Lohmann B, Le Rhun E, Silginer M, Epskamp M, Weller M. Interferon- β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02. *Oncol Lett* in press

Tobias Weiss

Zhu Y, Weiss T, Zhang Q, Sun R, Wang B, Yi X, Wu Z, Gao H, Cai X, Ruan G, Zhu T, Xu C, Lou S, Yu X, Gillet L, Blattmann P, Saba K, Fankhauser CD, Schmid MB, Rutishauser D, Ljubicic J, Christiansen A, Fritz C, Rupp NJ, Poyet C, Rushing E, Weller M, Roth P, Haralambieva E, Hofer S, Chen C, Jochum W, Gao X, Teng X, Chen L, Zhong Q, Wild PJ, Aebersold R, Guo T. High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification. *Mol Oncol.* 2019. doi: 10.1002/1878-0261.12570

Eisele G, Roelcke U, Conen K, Huber F, Weiss T, Hofer S, Heese O, Westphal M, Hertler C, Roth P, Weller M. Complementary and alternative medicine use by glioma patients in Switzerland. *Neurooncol Pract.* 2019;6(3):237-244

Schuster H, Shao W, Weiss T, Pedrioli PGA, Roth P, Weller M, Campbell DS, Deutsch EW, Moritz RL, Planz O, Rammensee HG, Aebersold R, Caron E. A tissue-based draft map of the murine MHC class I immunopeptidome. *Sci Data.* 2018;5:180157

Wirsching HG, Weiss T, Roth P, Weller M. [Basic principles of diagnosis and treatment of gliomas]. *Nervenarzt.* 2018;89(6):692-698

Happold C, Stojcheva N, Silginer M, Weiss T, Roth P, Reifenberger G, Weller M. Transcriptional control of O(6) -methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. *J Neurochem*. 2018

Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. *Cancer Res*. 2018;78(4):1031-1043

Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M, Roth P. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. *Clin Cancer Res*. 2018;24(4):882-895

Weiss T, Weller M, Roth P. Immunological effects of chemotherapy and radiotherapy against brain tumors. *Expert Rev Anticancer Ther*. 2016;16(10):1087-94

Weiss T, Weller M, Roth P. Immunotherapy for glioblastoma: concepts and challenges. *Curr Opin Neurol*. 2015;28(6):639-46